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Abstract
Leber Congenital Amaurosis (LCA) and Early Childhood Onset Severe Retinal Dystrophy are clinically and genetically
heterogeneous retinal disorders characterised by visual impairment and nystagmus from birth or early infancy. We
investigated the prevalence of sequence variants in AIPL1 in a large cohort of such patients (n = 392) and probed the
likelihood of disease-causation of the identified variants, subsequently undertaking a detailed assessment of the phenotype
of patients with disease-causing mutations. Genomic DNA samples were screened for known variants in the AIPL1 gene
using a microarray LCA chip, with 153 of these cases then being directly sequenced. The assessment of disease-causation of
identified AIPL1 variants included segregation testing, assessing evolutionary conservation and in silico predictions of
pathogenicity. The chip identified AIPL1 variants in 12 patients. Sequencing of AIPL1 in 153 patients and 96 controls found a
total of 46 variants, with 29 being novel. In silico analysis suggested that only 6 of these variants are likely to be disease-
causing, indicating a previously unrecognized high degree of polymorphism. Seven patients were identified with biallelic
changes in AIPL1 likely to be disease-causing. In the youngest subject, electroretinography revealed reduced cone
photoreceptor function, but rod responses were within normal limits, with no measurable ERG in other patients. An
increasing degree and extent of peripheral retinal pigmentation and degree of maculopathy was noted with increasing age
in our series. AIPL1 is significantly polymorphic in both controls and patients, thereby complicating the establishment of
disease-causation of identified variants. Despite the associated phenotype being characterised by early-onset severe visual
loss in our patient series, there was some evidence of a degree of retinal structural and functional preservation, which was
most marked in the youngest patient in our cohort. This data suggests that there are patients who have a reasonable
window of opportunity for gene therapy in childhood.
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Introduction
Leber Congenital Amaurosis (LCA) is an inherited retinal
dystrophy characterised by visual impairment and nystagmus from
birth or early infancy [1,2]. It is clinically and genetically
heterogeneous. There are currently 16 genes associated with
LCA which account for approximately 70% of patients, and
encode a variety of proteins, including those involved in
developmental and physiological pathways in the retina [1,2].
The safety and efficacy demonstrated by the on-going clinical
trials of gene therapy for LCA associated with RPE65 deficiency
have provided proof-of-principle for other forms of LCA; thereby
establishing a greater need for making timely and accurate
molecular diagnoses [3–5]. It is also important to investigate the
associated retinal phenotypes to help prioritise screening and to
identify which genetic subtypes have a window of opportunity
where photoreceptor rescue may be possible [1,2,6].
AIPL1 (aryl hydrocarbon receptor-interacting protein-like 1) is
expressed in rod and cone photoreceptors, and has a critical role in
cell viability [7,8]. It is required for the assembly of the
phototransduction protein, phosphodiesterase, in both rods and
cones [8]. Mutations in AIPL1 are associated with a form of LCA
that is characterised by maculopathy and a pigmentary retinop-
athy which is evident from a young age [9–13]. Retinal imaging
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studies have demonstrated significant loss of outer retinal structure
at the central macula, with areas of relative preservation
peripherally [9,11,13]. However, these findings principally relate
to adult patients, and the finding that the presumed loss of
photoreceptors on the basis of optical coherence tomography, is
more severe with age, suggests that younger patients may have a
greater degree of retained photoreceptors, which could be targeted
by gene-supplementation therapy. Autofluorescence (AF) imaging
undertaken in a recent study identified areas of retained AF at the
posterior pole, which may be consistent with the presence of viable
photoreceptors [9]. Importantly, retained rod function on dark-
adapted perimetry and pupillometry has also been observed in
patients, some of whom were in the third and fourth decades of life
[11].
In mouse models of Aipl1 deficiency, rapid complete degener-
ation of both rods and cones is seen within 4 weeks of age [14,15].
Significant rescue of photoreceptor structure and function has
been achieved using adeno-associated viral vector-mediated gene
supplementation in Aipl2/2 mouse models of LCA following
treatment of neonatal mice [9,16,17]. These studies suggest that a
similar approach may be effective in humans. Although most
patients have severe visual loss from infancy, a patient with a
hypomorphic AIPL1 genotype has been reported with a milder
later-onset retinitis pigmentosa-like phenotype [11]. Such patients
are more likely to respond to gene therapy and it may be
worthwhile to screen AIPL1 in patients with less severe forms of
inherited retinal disease.
We have undertaken a study to identify patients with AIPL1
mutations from our LCA and EOSRD cohort using a combina-
tion of microarray LCA chip analysis and direct sequencing, and
thereby establish the prevalence of AIPL1 sequence variants in our
patient population [18,19]. We have subsequently examined their
phenotype in detail to gain insights into disease severity, variability
and potential time-points that may be best to consider therapeutic
intervention.
Results
Molecular Investigations
The Asper LCA microarray chip identified AIPL1 sequence
variants in 12 patients. Sequencing of AIPL1 in 153 patients and
96 controls found a total of 46 variants (Table 1); with 29 being
previously unreported (Table 1). No novel nonsense, frameshift or
in/dels were found in the patient cohort.
Analysis of all variants for their effect on splicing is shown in
supplementary table 1 Table S1). Human splicing factor matrix
analysis showed that 22 variants showed the potential to affect
splicing in AIPL1. Without further experimental analysis, it is
difficult to decide which of these splicing effects would occur in
vivo.
In silico mutation analysis programs were used to identify which
of the 17 missense variants had the potential to be disease-causing
(Table 2). Variants p.Asp90His, p.Val96Ile and p.Thr114Ile are
known SNPs in AIPL1 (Tables 1 and 2). The substitution
p.Arg324Leu was identified in our control panel and predicted
to not be disease-causing by two of the analysis programs (Tables 1
and 2) and showed no effect on splicing, and was therefore
considered to be a SNP. Analysis of the variants, p.Tyr134Phe,
p.Ser198Thr, p.Lys214Arg and p.Pro376Ser, considered them to
be benign rare variants. Only p.Lys214Arg was predicted to
potentially have an effect on splicing. A second mutation was not
found in the patients harbouring these variants.
The pathogenicity of the variants p.His130Gln, p.Ser198Phe,
p.Gln298His and p.Pro366Arg was inconclusive with at least one
of the three programs suggesting that these changes could be
disease-causing. Only p.Gln298His showed the potential to break
its nearest acceptor splice site. They were also not found in
controls, nor listed on dbSNP. None of the patients with these
changes had a second variant identified. Therefore we were
unable to conclusively establish whether these variants are benign
rare variants or disease-causing mutations.
We believe that two previously reported mutations in AIPL1
that have been suggested to be disease-causing, are more likely to
be benign variants. We identified two patients who were
homozygous for p.Arg302Leu, with a further four patients found
to be heterozygous for this change, with no second mutation
identified (Table 1). This change has been previously published as
a mutation [20]. This allele has no published allele frequency in
white controls, but was detected in our laboratory in the
homozygous state in an unaffected parent of Indian descent
whose affected children have LCA caused by a homozygous
mutation in the gene RPGRIP1. All our patients with this change
were from the Indian subcontinent and the Middle-East,
suggesting it may be a polymorphism in these populations.
Another allele found in our patient cohort is p.Pro376Ser,
published as a mutation in 2000 [20]. This allele is not found in
white controls but has been found in African Americans at a low
frequency of 0.022 (Table 1). Interestingly, the patients in our
cohort with this change are of West African descent. We found one
patient who was homozygous for the change. Her affected half
sister was heterozygous for p.Pro376Ser, and we were unable to
find a second variant. This family is now being investigated for
other disease-causing genes. A third patient of Caribbean descent
was also found to have this change in the heterozygous state with
no second mutation. In silico analysis did not identify this variant as
likely to be disease-causing (Table 2).
Using a combination of sequencing to confirm Asper chip
variants plus complete sequencing of the entire coding region of
AIPL1, this study has identified seven patients with biallelic
changes in AIPL1 that are highly likely to be disease-causing
(Table 3). Interestingly, the microarray chip identified either one
or both AIPL1 variants in all 7 patients. Five patients were found to
have homozygous null mutations, one patient was a compound
heterozygote for a missense and a nonsense mutation, and one
patient was a compound heterozygote for a missense and splice site
mutation (Table 3). One novel change was identified (p.Gly64Arg),
with the most frequent mutation identified being p.Trp278Ter.
Clinical Assessment
Seven patients were identified harbouring two potential disease-
causing alleles in AIPL1. Clinical findings are summarised in
Table 4. All subjects presented at birth or early infancy (within 6
months) with nystagmus; with reduced vision also noted in six of
these patients. The age at examination ranged from 2 years to 36
years, with two patients examined at an early age (2 years; cases 3
and 7). Photoattraction (light staring) was reported in two subjects.
Only case 7 (2 years of age) with a BCVA of 0.5 LogMAR, had
a visual acuity better than perception of light. Four subjects (aged
17 to 36 years) had evidence of cataract (3 had posterior
subcapsular lens opacity, and 1 nuclear sclerosis), with 2 of these
patients also having keratoconus (Table 4). Three patients had a
myopic refractive error, whilst one had moderate hypermetropia.
An increasing degree and extent of retinal pigmentation,
including bone spicule formation, was noted with increasing age;
with the two youngest subjects (cases 3 and 7) having no retinal
pigmentation (Table 4; Figure 1). Two patients were found to have
retinal white dots (cases 1 and 6). The severity of maculopathy also
increased with age, with patients developing frank full-thickness
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Table 1. Variants identified in AIPL1 in patients and controls.
rs Number Position
Nucleotide
Change
Amino Acid
Change
Allele Freq in
patients (n=153)
Allele freq in
controls (n =96)
HapMap CEU
Allele Freq
AIPL1
disease
allele
rs7211442 Intron 1 c.1-106C.A C= 0.974, A = 0.026 C= 1.000, A = 0.000
Novel Intron 1 c.1-45C.A C= 1.000, A = 0.000 C= 0.99, A = 0.01
Novel Exon 1 c.51G.A p.Leu17Leu G= 0.997, A = 0.003 G= 1.000, A = 0.000
Novel Intron 2 c.97-16C.T C= 1.000, T = 0.000 C= 0.995, T = 0.005
rs11650007 Exon 2 c.111C.T p.Phe37Phe C= 0.977, T = 0.023 C= 0.979, T = 0.021 C= 0.967, A = 0.033
Novel Exon 2 c.190G.A p.Gly64Arg G= 0.997, A = 0.003 G= 1.000, A = 0.000 Yes
Novel Exon 2 c.264G.A p.Trp88Ter G= 0.987 A= 0.013 G= 1.000, A = 0.000 Yes
Novel Exon 2 c.267C.T p.Cys89Cys C= 1.000, T = 0.000 C= 0.979, T = 0.021
rs12449580 Exon 2 c.268G.C p.Asp90His G = 0.895, C = 0.105 G= 0.823, C = 0.177 G=0.667, C = 0.333
Novel Intron 2 c.277-30insG G= 0.997, GG= 0.003 G= 1.000, insG = 0.000
rs12453262 Intron 2 c.277-10 A.G A= 0.775, G = 0.225 A= 0.823, G = 0.177 A= 0.456, G = 0.544
Novel Intron 2 c.277-2A.G A= 0.997, G = 0.003 A= 1.000, G = 0.000 Yes
rs62619924 Exon 3 c.286G.A p.Val96Ile G = 0.984, A = 0.016 G= 1.000, A = 0.000 G=0.992, A = 0.008
rs8075035 Exon 3 c.300A.G p.Leu100Leu A= 0.709, G = 0.291 A= 0.833, G = 0.167 A= 0.372, G = 0.372
rs8069375 Exon 3 c.341C.T p.Thr114Ile C = 0.99, T = 0.01 C= 1.000, G = 0.000 C= 0.926, T = 0.074
Novel Exon 3 c.390C.A p.His130Gln C= 0.997, A = 0.003 C= 1.000, A = 0.000
rs16955851 Exon 3 c.496A.T p.Tyr134Phe A= 0.999 T = 0.001 A= 1.000, T = 0.000 A= 1.000, T = 0.000{
Novel Exon 3 c.439C.T p.Leu147Leu C= 0.993, T = 0.007 C= 0.993, T = 0.007
rs925615 Intron 3 c.466-26T.C T= 0.938, C = 0.062 T = 0.906, C = 0.094 T = 0.903, C = 0.097
Novel Intron 3 c.466-2A.G A= 0.993, G = 0.007 A= 1.000, G = 0.000
rs62637009 Exon 4 c.487C.T p.Gln163Ter C = 0.993, T = 0.007 C= 1.000, T = 0.000 N/P Yes
Novel Exon 4 c.555A.G p.Gly185Gly A= 0.997, G = 0.003 A= 1.000, G = 0.000
Novel Exon 4 c.592T.A p.Ser198Thr T = 0.984, A = 0.016 T = 1.000, A = 0.000
Novel Exon 4 c.593C.T p.Ser198Phe C= 0.997, T = 0.003 C= 1.000, T = 0.000
Novel Exon 4 c.641A.G p.Lys214Arg A= 0.997, G = 0.003 A= 1.000, G = 0.000
rs925616 Intron 4 c.642+48G.A G= 0.791, A = 0.209 G= 1.000, A = 0.000 G=0.625, A = 0.375
rs2292545 Intron 4 c.642-33C.T C= 0.863, T = 0.137 C= 0.964, T = 0.036 C= 0.717, T = 0.283
rs2292546 Exon 5 c.651A.G p.Pro217Pro A= 0.614, G = 0.386 A= 0.724, G = 0.276 G=0.717, A = 0.283
Novel Exon 5 c.678G.A p.Glu226Glu G= 1.000, A = 0.000 G= 0.974, A = 0.026
rs62637013 Exon 5 c.784G.A p.Gly262Ser G= 0.997, A = 0.003 G= 1.000, A = 0.000 N/P Yes
Novel Intron 5 c.784+8G.C G= 0.984, C = 0.016 G= 1.000, C = 0.000
rs7222126 Intron 5 c.784+18G.A G= 0.984, A = 0.016 G= 1.000, A = 0.000 N/P
Novel Intron 5 c.784+26G.C G= 0.987, C = 0.013 G= 1.000, C = 0.000
rs62637014 Exon 6 c.834G.A p.Trp278Ter G= 0.98, A = 0.02 G= 1.000, A = 0.000 N/P Yes
Novel Exon 6 c.894G.C p.Gln298His G = 0.997, C = 0.003 G= 1.000, C = 0.000
rs62637015 Exon 6 c.905G.T p.Arg302Leu G= 0.967, T = 0.033 G= 1.000, T = 0.000 N/P ?
Novel Exon 6 c.971G.T p.Arg324Leu G= 0.997, T = 0.003 G= 0.99, C = 0.01
Novel Exon 6 c.1005C.A p.Pro335Pro C= 1.000, A = 0.000 G= 0.99, C = 0.01
Novel Exon 6 c.1023G.A p.Glu341Glu G= 1.000, A = 0.000 G= 0.974, A = 0.026
Novel Exon 6 c.1032A.G p.Ala344Ala A= 0.99, G = 0.01 A= 1.000, G = 0.000
Novel Exon 6 c.1038A.G p.Ser346Ser A = 0.99, G = 0.01 A= 1.000, G = 0.000
Novel Exon 6 c.1091C.G p.Ala364Gly C= 0.997, G = 0.003 C= 1.000, G = 0.000
Novel Exon 6 c.1097C.G p.Pro366Arg C= 0.993, G = 0.007 C= 1.000, G = 0.000
Novel Exon 6 c.1110A.T p.Pro370Pro A= 1.000, T = 0.000 A= 0.995, T = 0.005
rs61757484 Exon 6 c.1126C.T p.Pro376Ser C = 0.984, T = 0.016 C= 1.000, T = 0.000 C= 0.933, A = 0.067* ?
Novel Exon 6 c.1164A.G 39UTR A= 0.997, G = 0.003 A= 1.000, G = 0.000
*Allele frequency taken from AGI-ASP population on dbSNP. This population is from the Cornell apparently healthy population and the frequency is based on 60
chromosomes.
{The minor allele has a frequency in the African American population of 0.022.
doi:10.1371/journal.pone.0032330.t001
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retinal atrophy over time; again the two youngest subjects had a
milder phenotype, with either a normal appearing macula or mild
retinal pigment epithelial mottling (Table 4; Figure 1). Optic nerve
pallor was noted in the two oldest subjects in our series, with one
patient (case 6) having disc drusen.
Autofluorescence images were obtained in 2 patients (Figure 1).
In case 1 there was evidence of a mild generalised reduction in AF
at the posterior pole, with relatively preserved macular AF.
Reduced foveal AF was observed, corresponding to the atrophy
seen clinically in case 6, with otherwise relatively well preserved
macular AF.
Electrophysiological assessment was undertaken in 6 patients
and revealed no measurable rod or cone responses in five subjects
(cases 2 to 6). It is of note that in one of the youngest subjects (case
7), rod responses were within normal limits, with recordable but
significantly reduced cone photoreceptor function (Figure 2).
Discussion
We have identified seven patients who harbour biallelic
mutations in AIPL1 that are highly likely to be disease-causing.
The detailed molecular screening we have undertaken in a large
panel of patients recruited from a single institution has
demonstrated the previously unrecognised high degree of
polymorphism present in AIPL1, which complicates the interpre-
tation of any sequence variants that are found. This may explain
the difference between the previously reported prevalence of
AIPL1-associated disease (approximately 7%), and that observed in
our study (approximately 2%) [20]. We have carefully probed the
likely disease association of each of the variants in order to
establish as reliably as possible a molecular diagnosis. This is
critical if there is to be any gene-specific therapeutic interventions.
In keeping with previous studies, we have identified the
p.Trp278Ter as the most common disease variant, and also
shown that null alleles are the most prevalent disease-associated
variants [9–11,20].
Direct sequencing of a large number of patients in a condition
that is known to be caused by at least 16 genes is a time consuming
and expensive procedure. The use of APEX chips such as the
Asper LCA chip can be an effective first screen allowing patients
with known mutations to be identified quickly and then removed
from the cohort for any further screening. In this study we
screened 392 individuals using the LCA APEX chip, with one or
more alleles in an LCA gene identified in approximately 40% of
these patients. We elected to screen 153 of the remaining patients
who either had 1 or more alleles in AIPL1 or had no alleles
identified in other genes. This number was based on human,
financial and time constraints. It is plausible that by not
sequencing the remaining 239 DNAs, we may have missed some
AIPL1 positive patients. Direct sequencing of the 306 alleles (153
patients) only identified 1 variant that was considered to have the
potential to be disease-causing; a frequency of detection for AIPL1
alleles of 0.33%. On this basis, sequencing the remaining 239
DNAs could be predicted to identify 0.78 alleles, which would not
have increased the number of patients identified in this study.
Newer techniques, such as next generation sequencing (NGS) of
either the whole genome or exome, will allow a higher rate of
mutation detection, and as the cost decreases NGS will be used
more commonly
This large screen only identified one potential novel change,
p.Gly64Arg in patient 7 (Table 3). This variant was not found in
the other 152 patients we screened, nor in the 96 ethnically
matched controls. In silico analysis suggests that it has the potential
to be disease-causing (Table 3). We have included the variant
Table 2. In silico analysis of all missense variants identified in AIPL1 in this study.
Change SIFT Polyphen 2 pMUT Consensus
Prediction
Tolerance
index Prediction
Hum Var
score
NN
output Reliability Prediction
p.Gly64Arg Intolerant 0.00 Probably damaging 1.000 0.6670 3 Pathological Disease causing
p.Asp90His Tolerant 0.26 Benign 0.241 0.4719 0 Neutral SNP(rs12449580)
p.Val96Ile Tolerant 0.20 Benign 0.064 0.0794 8 Neutral SNP(rs62619924)
p.Thr114Ile Tolerant 0.19 Benign 0.48 0.7499 4 Pathological SNP (rs8069375)
p.His130Gln Tolerant 0.71 Probably damaging 0.961 0.3446 3 Neutral Uncertain
p.Tyr134Phe Tolerant 0.26 Benign 0.448 0.0715 8 Neutral Benign rare variant
p.Ser198Thr Tolerant 0.60 Benign 0.002 0.2553 4 Neutral Benign rare variant
p.Ser198Phe Tolerant 0.07 Benign 0.072 0.6788 3 Pathological Uncertain
p.Lys214Arg Tolerant 0.70 Possibly damaging 0.688 0.0734 8 Neutral Benign rare variant
p.Gly262Ser Tolerant 0.86 Possibly damaging 0.608 0.3055 3 Neutral Benign rare variant
p.Gln298His Tolerant 0.06 Benign 0.174 0.5535 1 Pathological Uncertain
p.Arg302Leu Tolerant 0.16 Benign 0.003 0.8448 6 Pathological Uncertain
p.Arg324Leu Tolerant 0.20 Benign 0.204 0.8587 7 Pathological Uncertain
p.Ala364Gly Tolerant 0.48 N/D N/D 0.1970 6 Neutral Benign rare variant
p.Pro366Arg Tolerant 0.10 N/D N/D 0.2874 5 Pathological Uncertain
p.Pro376Ser Intolerant 0.00 N/D N/D 0.2874 4 Neutral Uncertain
N/D=Unable to make a prediction due to lack of data.
If all three programs agree that the change is pathological, then the consensus is disease causing. If one or two out of three programs agree with the variant being
pathological, this is labelled uncertain. If all three agreed the change was benign (or in the case of polyphen 2 possibly damaging), then the variant is labelled a SNP (if rs
number is available) or Benign rare variant.
doi:10.1371/journal.pone.0032330.t002
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p.Gly262Ser, present in patient 6, as a disease-causing mutation. It
has been previously published as a disease-causing allele [20]. In
silico analysis shows that only 1 out of the 3 programs suggests that
it is disease-causing (Table 2). This variant may have an effect on
splicing as shown in supplementary table 1. It is paired with the
published mutation c.277-2A.G28. Both of these changes were
previously published in a heterozygous state with the known
nonsense mutation p.Trp278Ter [20]. Expression of p.Gly262Ser
has suggested that the mutated protein will still bind to NUB1
[21], but may increase its affinity compared to the wildtype protein
[22]. This variant does not affect the ability of AIPL1 to interact
with Hsp90 and Hsp70 [23].
We found at least 4 novel variants (p.His130Gln, p.Ser198Phe,
p.Gln298His and p.Pro366Arg) for which in silico analysis proved
inconclusive. We were also not able to find a second disease-
causing variant in these patients. This may either indicate that
these variants are benign and rare in the population and not
disease-causing, or that these patients have a second disease
mutation which was missed by Sanger sequencing of the coding
regions of AIPL1.
Two previously reported disease-associated variants are more
likely to represent rare ethnic SNPs. We believe that our patients
provide evidence that p.Arg302Leu and p.Pro376Ser are not
AIPL1 mutations. For p.Arg302Leu we identified two brothers
who were heterozygous for the change but homozygous for a
mutation in RPGRIP1. Further examination of the family showed
no second mutation and that their unaffected father was
homozygous for p.Arg302Leu. This change has been previously
published as a mutation but has only been seen in patients of
Indian/Middle East descent. Further evidence supporting a lack of
pathogenicity of the p.Arg302Leu variant includes that this amino
acid residue is not conserved across species, in expression analysis
it does not affect the way AIPL1 interacts with NUB1 [21,22],
Hsp70 or Hsp90 [23], and also does not affect the ability of AIPL1
to interact with farnesylated proteins [24]. We also propose that
p.Pro376Ser, previously published as a mutation is a rare SNP in
the African population. dbSNP has a frequency for this SNP as
0.022 in the African American population. All three patients in
our cohort were of West African descent. In silico analysis did not
identify this variant as likely to be disease-causing (Table 2) and in
vitro expression of the mutant protein has shown that it will still
interact with NUB1 [21].
All seven subjects presented at birth or early infancy (within 6
months) with nystagmus; with reduced vision also noted in six of
these patients. Consistent with previous reports, photoattraction
was described in two subjects; this is not a specific finding as it has
been described in other LCA/EOSRD genotypes [1,2,9].
Although refractive data was available in only 4 subjects, it is
interesting that 3 of these had a moderate to high myopic
refractive error, in contrast to the predominant hypermetropia
recently reported [9,11]. Only one patient had a BCVA better
than perception of light, with 0.5 LogMAR recorded at 2 years of
age. In keeping with previous studies, cataract (60% patients) and
keratoconus (30%) was common in our cohort [9,10,20].
An increasing degree and extent of retinal pigmentation,
including bone spicule formation, was noted with increasing age,
with the two youngest subjects not having any evidence of retinal
pigmentation. The severity of maculopathy also increased with
age, with patients developing marked atrophy over time. The two
youngest subjects had a milder phenotype, either a normal
appearing macula or mild retinal pigment epithelial mottling.
These findings suggest that at the early stages of disease there may
be a relative degree of peripheral and central preservation of
retinal structure, with clear implications for therapeutic interven-
tions. Optical coherence tomography (OCT) in infancy, using
hand-held probes, would be valuable to investigate this further. In
older subjects there is OCT evidence of reduced retinal thickness
and/or integrity of retinal lamination in the presence of relatively
normal ophthalmoscopic findings; although parafoveal retinal
structure has been shown to be preserved in some patients [9,11].
However, patients with AIPL1 disease have yet to be identified and
studied in infancy with high-resolution quantitative retinal
imaging. Adaptive optics imaging, which is directly complemen-
tary to OCT, is likely to be helpful in establishing in vivo whether
target photoreceptors are present and to what extent and at what
retinal locations.
In keeping with the clinical examination findings suggestive of a
degree of retinal architecture preservation in younger patients,
autofluorescence (AF) imaging, whilst showing evidence of
generalised reduction in AF at the posterior pole, also demon-
strated relatively preserved macular AF; suggestive of outer
segment turnover and thereby a degree of structurally intact
photoreceptors in complex with retinal pigment epithelial cells.
Interestingly, the retained AF signal that was observed in the two
imaged patients had a BCVA of perception of light. These
observations are in agreement with those reported by Testa et al
recently [9].
No measurable rod or cone ERG responses were observed in
five subjects, in keeping with previous reports [9–11]. It is of note
that we have identified a patient (2 years old) with rod responses
within normal limits, with recordable but significantly reduced
cone photoreceptor function. This important finding of preserved
retinal function has also recently been reported in a case series of 3
young patients with AIPL1-associated disease [25].
Most reported cases of AIPL1-associated disease have an early
onset severe retinal dystrophy, which poses challenges with regard
Table 3. Patients with disease-causing mutations in AIPL1.
Patient Allele 1 Allele 2 Diagnosis Ethnicity Consanguinity
1 p.Trp278Ter p.Trp278Ter LCA African No
2 p.Trp278Ter p.Trp278Ter LCA White No
3 p.Gln163Ter p.Gln163Ter LCA Middle-East Yes
4 p.Trp88Ter p.Trp88Ter LCA Pakistani Yes
5 p.Trp88Ter pTrp88Ter LCA Pakistani Yes
6 c.277-2A.G p.Gly262Ser LCA White No
7 pGly64Arg p.Trp278Ter LCA White No
doi:10.1371/journal.pone.0032330.t003
Leber Congenital Amaurosis Associated with AIPL1
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32330
T
a
b
le
4
.
Su
m
m
ar
y
o
f
C
lin
ic
al
C
h
ar
ac
te
ri
st
ic
s
o
f
P
at
ie
n
ts
w
it
h
D
is
e
as
e
C
au
si
n
g
M
u
ta
ti
o
n
s
in
A
IP
L1
.
C
a
se
E
th
n
ic
it
y
M
u
ta
ti
o
n
A
g
e
a
t
o
n
se
t
P
re
se
n
ti
n
g
sy
m
p
to
m
s
A
g
e
a
t
e
x
a
m
i-
n
a
ti
o
n
(y
e
a
rs
)
B
C
V
A
L
o
g
M
A
R
(O
D
;
O
S
)
N
y
st
a
-
g
m
u
s
S
tr
a
b
i-
sm
u
s
P
u
p
il
s
P
A
V
/
P
A
T
P
ig
m
e
n
ta
ry
re
ti
n
o
p
a
th
y
M
a
cu
lo
p
a
th
y
D
is
c
p
a
ll
o
r
/d
ru
se
n
W
h
it
e
re
ti
n
a
l
d
o
ts
C
a
ta
ra
ct
/
k
e
ra
to
co
n
u
s
R
e
fr
a
ct
io
n
O
th
e
r
fe
a
tu
re
s
1
A
fr
ic
an
p
.T
rp
2
7
8
T
e
r
p
.T
rp
2
7
8
T
e
r
B
ir
th
P
o
o
r
vi
si
o
n
,
n
ys
ta
g
m
u
s
1
9
P
L;
P
L
Y
N
A
m
N
M
o
d
e
ra
te
,
b
o
n
e
sp
ic
u
le
s
M
ild
M
o
tt
lin
g
N
Y
N
M
o
d
e
ra
te
m
yo
p
ia
(2
5
.5
0
)
2
W
h
it
e
p
.T
rp
2
7
8
T
e
r
p
.T
rp
2
7
8
T
e
r
B
ir
th
P
o
o
r
vi
si
o
n
,
n
ys
ta
g
m
u
s
2
4
P
L;
P
L
Y
N
N
D
N
M
o
d
e
ra
te
,
b
o
n
e
sp
ic
u
le
s
A
tr
o
p
h
y
N
N
N
S
N
D
3
A
ra
b
p
.G
ln
1
6
3
T
e
r
p
.G
ln
1
6
3
T
e
r
2
m
o
n
th
s
P
o
o
r
vi
si
o
n
,
n
ys
ta
g
m
u
s
2
P
L;
P
L
Y
ET
A
m
P
A
T
N
o
n
e
N
o
n
e
N
N
N
M
o
d
e
ra
te
h
yp
e
ro
p
ia
(+
6
.5
0
)
4
P
ak
is
ta
n
i
p
.T
rp
8
8
T
e
r
p
.T
rp
8
8
T
e
r
B
ir
th
P
o
o
r
vi
si
o
n
,
n
ys
ta
g
m
u
s
3
0
P
L;
P
L
Y
X
T
A
m
N
M
o
d
e
ra
te
A
tr
o
p
h
y
Y
N
P
S,
K
C
N
D
5
P
ak
is
ta
n
i
p
.T
rp
8
8
T
e
r
p
.T
rp
8
8
T
e
r
B
ir
th
P
o
o
r
vi
si
o
n
,
n
ys
ta
g
m
u
s
3
6
P
L;
P
L
Y
X
T
A
m
N
M
o
d
e
ra
te
A
tr
o
p
h
y
Y
N
P
S,
K
C
N
D
6
W
h
it
e
c.
2
7
7
-2
A
.
G
p
.G
ly
2
6
2
Se
r
6 m
o
n
th
s
P
o
o
r
vi
si
o
n
,
n
ys
ta
g
m
u
s
1
7
P
L;
P
L
Y
N
A
m
P
A
T
M
o
d
e
ra
te
A
tr
o
p
h
y
D
R
Y
P
S
M
o
d
e
ra
te
m
yo
p
ia
(2
5
.0
0
)
7
W
h
it
e
p
.G
ly
6
4
A
rg
p
.T
rp
.2
7
8
T
e
r
2
.5
m
o
n
th
s
N
ys
ta
g
m
u
s
2
0
.5
B
EO
Y
N
N
o
rm
al
N
N
o
n
e
M
ild
M
o
tt
lin
g
N
N
N
H
ig
h
m
yo
p
ia
(2
8
.5
0
)
H
e
ad
n
o
d
d
in
g
B
C
V
A
–
b
e
st
co
rr
e
ct
e
d
vi
su
al
ac
u
it
y;
P
L
-
p
e
rc
e
p
ti
o
n
o
f
lig
h
t;
B
EO
–
b
o
th
e
ye
s
o
p
e
n
;P
L
-
p
e
rc
e
p
ti
o
n
o
f
lig
h
t;
X
T
-
e
xo
tr
o
p
ia
;E
T
-
e
so
tr
o
p
ia
;N
–
n
o
;N
D
–
n
o
t
d
o
n
e
;A
m
–
am
au
ro
ti
c;
N
S
-
n
u
cl
e
ar
sc
le
ro
si
s;
O
D
-
ri
g
h
t
e
ye
;O
S
-
le
ft
e
ye
;
P
A
T
-
p
h
o
to
at
tr
ac
ti
o
n
;
P
A
V
-
p
h
o
to
av
e
rs
io
n
;
D
R
-
d
ru
se
n
;
P
S
-
p
o
st
e
ri
o
r
su
b
ca
p
su
la
r
ca
ta
ra
ct
;
K
C
–
ke
ra
to
co
n
u
s;
Y
–
ye
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
3
2
3
3
0
.t
0
0
4
Leber Congenital Amaurosis Associated with AIPL1
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e32330
to potential treatment. The significant rescue demonstrated in
animal models with severe rapidly progressive disease by several
independent studies is supportive of a potential therapeutic effect
in patients [9,16,17]. The severe phenotype seen in most older
patients suggests that therapy will need to be given in early
childhood. Our identification of a patient who at a young age (2
years) has evidence of a milder phenotype, including normal
retinal examination, useful central vision, normal pupil responses,
and relatively preserved electrophysiological function (rod to a
greater extent than cone), suggests that there are patients who
have a reasonable window of opportunity for therapy in
childhood. It is of note that this patient harbours a novel missense
mutation rather than the more common homozygous null
genotype, and this potentially hypomorphic allele may underlie
her milder phenotype. It is possible that patients with a milder
phenotype have not been identified as only patients with severe
disease have been screened. There does appear to be a subgroup
of patients with less severe later onset disease who may also be
amenable to therapy, suggesting that later onset cohorts should
also be screened for AIPL1 mutations [11].
Identifying patients shortly after birth will clearly be challeng-
ing, although the advent of next generation sequencing is likely to
lead to the early identification of patients with a wider range of
phenotypes (screening of exons of all genes known to cause retinal
disease in patients will become more common than screening
directed by patient phenotype). Earlier treatment whilst likely to be
more efficacious from the point of view of better retained retinal
structure and a lesser degree of established amblyopia, will be
complicated by the inherent difficulty of reliably identifying
treatment responses in pre-verbal children; an area of increasing
research importance.
In summary, we have demonstrated the polymorphic nature of
AIPL1 following analysis of a large panel of patients and control
subjects, and thereby highlighted the difficulty of reliably ascribing
disease causation to identified variants. The molecular character-
isation of LCA is important for information on prognosis, genetic
counseling and also with the advent of gene therapy trials, for
identification of suitable candidates for potential therapy. Despite
the severe AIPL1-associated visual loss in our patient series, there
was some evidence of a degree of retinal structural and functional
Figure 1. Colour fundus photographs and autofluorescence imaging of patients with AIPL1-associated retinal dystrophy. A. Colour
fundus photograph of the right eye of case 2 at age 24 years, showing typical findings in an older subject with AIPL1-related retinal dystrophy.
Characteristic features include bone spicule retinal pigmentation in the mid-periphery, macular atrophy and optic nerve pallor. B. Colour fundus
photograph of the left eye of case 3 at age 2 years. The fundus appears unremarkable with minimal changes at the fovea. C. Autofluorescence (AF)
imaging of case 1 at age 19 years showing evidence of a mild generalised reduction in AF at the posterior pole, with relatively preserved macular AF.
D. Autofluorescence imaging in case 6 at age 17 showing good preservation of macular AF and some loss of foveal AF secondary to atrophy.
doi:10.1371/journal.pone.0032330.g001
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preservation, which was most marked in the youngest patient in
our cohort, suggesting that there are patients who may be good
candidates for gene therapy in childhood.
Methods
All patients in this study had a clinical diagnosis of LCA or
EOSRD, with onset before 6 years of age. All provided informed
written consent as part of a research project approved by
Moorfields Eye Hospital Ethics Committee, and all investigations
were conducted in accordance with the principles of the
Declaration of Helsinki. Written informed consent was obtained
from the next of kin, carers or guardians on the behalf of the
children participating in this study.
Molecular Investigations
Blood samples were collected and DNA extracted using the
Puregene blood extraction kit (Invitrogen, Paisley, UK) following
manufacturer’s instructions. The patient panel consisted of 392
unrelated probands; 26% had parents who were related. Seventy
percent of the DNA samples were from white subjects, of either
British or other European backgrounds; 21% were of Asian
extraction, mostly Pakistani or Indian; 3% were of Middle-Eastern
origin; 1.6% were African; 0.6% were Chinese and the remainder
were of mixed backgrounds. The control panel consisted of 96
DNA samples originating from a control population of randomly
selected, non-related white UK blood donors (ECACC Human
Random Control-1 DNA panel).
APEX Chip. A genomic DNA sample from 392 unrelated
affected patients was sent to Asper Ophthalmics Ltd for analysis as
described previously [18,19]. 112 patients were analysed using the
current LCA microarray test, that contains 641 disease-associated
sequence variants identified in 13 LCA or early-onset retinitis
pigmentosa genes: AIPL1, CRB1, CRX, GUCY2D, LRAT, TULP1,
MERTK, CEP290, RDH12, RPGRIP1, LCA5, RPE65, and
SPATA7. Four earlier versions of the LCA chip were also used
during the course of the study; 134 patients using a chip containing
8 genes and 345 variants, 58 patients analysed for 10 genes and
435 variants, 16 patients analysed for 11 genes and 451 variants
and 72 patients analysed for 12 genes and 493 variants. Samples in
which mutations were identified in other LCA genes were
excluded from further study. The majority of this work has been
published elsewhere [26–30].
Mutation screening. A total of 153 patient DNA samples
(153/392) then underwent bi-directional sequencing of all 6 exons
of the AIPL1 gene (NM_014336.3), including splice-site junctions.
These 153 subjects were selected on the basis of either no
mutations identified on the microarray chip or that they had been
found to harbour one or more AIPL1 sequence variants. Primer
sequences are available upon request. All standard polymerase
chain reactions (PCR) were performed in a total volume of 30 ml
containing 200 mM dNTPs (Bioline London, UK), 20 mM of each
primer, 16 reaction buffer, 1.5 mM MgCl2 (Bioline), 1 unit of
Biotaq (Bioline), and 100 ng of DNA. PCR was carried out on a
PTC200 DNA engine thermal cycler (Bio-Rad, Hemel
Hempstead, UK). Cycling conditions were as follows: 2 minutes
denaturation at 94uC, followed by 35 cycles of 94uC for
30 seconds, annealing temperature for 30 seconds and extension
at 72uC for 30 seconds. A final extension of 72uC for 5 minutes
completed the cycling conditions.
PCR products were visualised on a 2% agarose gel containing
0.05% ethidium bromide. The products were cleaned using
multiscreen PCR filter plates (Catalogue no LSKMPCR10,
Millipore, Watford, UK) prior to sequencing. PCR products were
sequenced directly using the ABI Prism Big Dye terminator Kit
(V3.1) in a 10 ml reaction. Samples were purified using the
Figure 2. Scotopic and photopic ERG recordings of patient case 7. ERGs recorded from case 7 aged 14 months, using skin electrodes to a
range of flash strengths (Grass (gr) 1–16) presented scotopically and photopically are shown above age-matched control data in the lower grey panel.
These ERGs indicate cone photoreceptor dysfunction; evidenced by markedly reduced photopic cone and 30 Hz flicker ERGs, and a scotopic red flash
ERG that shows predominance of the later rod dominated b-wave (arrowed). The scotopic (gr4) mixed rod cone waveform lacks an a-wave and the
time to peak is increased. In contrast predominantly rod mediated function is within the normal range; evidenced by the normal a-wave to a maximal
scotopic flash and rod driven b-wave to a scotopic dim blue flash.
doi:10.1371/journal.pone.0032330.g002
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Montage cleanup kit (catalogue no LSK509624, Millipore) prior to
being run on an ABI applied biosystems 3730 DNA sequencer
(Applied Biosystems, Foster City, CA, USA).
Electropherograms were analysed for sequence changes using
DNAStar computational software (DNAStar, Inc., USA). Se-
quencing data obtained from PCR products were analysed using
SeqMan, a programme designed to detect potential alterations in
the sequence. Any sequence changes identified were checked
visually. When family samples were available segregation of
potentially disease-causing variants was investigated. Missense
mutations were analysed using 3 software prediction programs:
SIFT (Sorting Intolerant from Tolerance (http://sift.jcvi.org/)
[31], PolyPhen2 (http://genetics.bwh.harvard.edu/pph/index.
html) [32] and pMUT (http://mmb.pcb.ub.es/PMut/) [33]. All
variants were also analysed for their effect on splicing using the
Human Splicing finder programme version 2.4.1 (http://www.
umd.be/HSF/).
Clinical Assessment
Patients harbouring variants that were likely to be disease-
causing underwent clinical testing. Clinical evaluation included
best-corrected visual acuity (BCVA) and dilated fundus examina-
tion. Colour fundus photography and fundus autofluorescence
(AF) imaging using a confocal scanning laser ophthalmoscope
(Heidelberg Retina Angiogram, HRA 2; Heidelberg Engineering,
Heidelberg, Germany) was undertaken.
Electrophysiological assessment was performed, including a full-
field electroretinogram (ERG) and pattern ERG (PERG),
incorporating the protocols recommended by the International
Society for Clinical Electrophysiology of Vision (ISCEV); or using
a modified paediatric ERG protocol with skin electrodes, as
previously described [34–38].
Supporting Information
Table S1 Analysis of allelic variants for their effect on
splicing. Analysis of 46 variants identified in AIPL1 using the
Human splicing finder version 2.4.1 reporting the results from the
HSF matrix. The values for the wild type and mutant sequences
are showed. The larger the difference between the values the
greater that change that the variant can affect the splice site.
(DOC)
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